GSK’s Q3 2015 results highlighted improved performance from the products containing Skyepharma’s dry powder inhalation formulation technologies. The Ellipta® range of products continued to post sales growth with combined sales in Q3 increasing 29% from Q2. We expect the positive momentum to continue going forward and make no changes to our forecasts at this stage. We believe Skyepharma has a highly attractive offering and remain positive on its outlook.
29 Oct 2015
Supportive GSK Q3 2015 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Supportive GSK Q3 2015 results
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
29 Oct 2015 -
Author:
Sheena Berry -
Pages:
3
GSK’s Q3 2015 results highlighted improved performance from the products containing Skyepharma’s dry powder inhalation formulation technologies. The Ellipta® range of products continued to post sales growth with combined sales in Q3 increasing 29% from Q2. We expect the positive momentum to continue going forward and make no changes to our forecasts at this stage. We believe Skyepharma has a highly attractive offering and remain positive on its outlook.